The backtest results show that ABVX experienced poor short-term performance following earnings beats, with 0% win rates at 3 and 10 days and negative returns of -12.07% and -21.09%, respectively. However, the 30-day win rate improves to 50%, and the 30-day return is nearly flat at -1.23%, indicating some recovery over a longer horizon. This suggests that while immediate reactions to earnings beats were negative, the stock may stabilize or recover over time. Investors should be cautious about short-term trades post-earnings beat and consider longer holding periods for potential gains.

backtest_data

The backtest results for ABVX show a consistent 50% win rate across 3-day, 10-day, and 30-day periods following earnings misses, with returns of 12.11%, 1.61%, and 22.72% respectively. This indicates a mixed but occasionally positive price reaction to earnings misses. The maximum return reached 74.04% on day 33, suggesting potential for significant gains over a longer horizon despite average short-term outcomes. Investors might consider a cautious approach, recognizing that ABVX can still offer upside opportunities after earnings disappointments but with balanced risk.

The backtest results reveal that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.29% observed 15 days after the event. This minimal positive return suggests that earnings beats do not strongly drive stock performance in this sector over the tested period.

The analysis indicates that despite frequent earnings beats, the industry shows limited upside reaction, reflecting possible market skepticism or other overriding factors.

Investors should be cautious about relying solely on earnings beats as a signal for gains in the Biotechnology Industry.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact, with a maximum return of -0.08% observed three days after the event. This negligible effect suggests that the market does not strongly react to earnings misses within this sector over the tested period.

The analysis indicates that investors may not need to adjust their positions based solely on earnings misses in Biotechnology stocks, as these events do not materially influence returns.

Therefore, investment strategies should consider other factors beyond earnings misses when evaluating Biotechnology industry stocks.

Backtest ABVX Earning Beats Expectations

Find all upcoming company earnings reports scheduled for sep 14 2026. Get details on which companies are reporting and their expected results.

Calendar